| |
Progress toward curing HIV infections with hematopoietic stem cell transplantation/NIAID Workshop
|
| |
| |
Download the PDF here
Download the PDF here
Clinical Infectious Diseases Advance Access published October 1, 2014
Stephen T. Smiley1, Anjali Singh1, Sarah W. Read1, Opendra K. Sharma1, Diana Finzi1, Clifford Lane2 and Jeffrey S. Rice3
1Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland
2Clinical and Molecular Retrovirology Section, Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland
3Division of Allergy, Immunology, and Transplantation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD
Brief Summary/Key points: To date, only one person seems to have been cured of HIV infection. This report describes efforts to exploit HSCT to cure HIV in cancer patients requiring such procedures and in the broader community of HIV infected persons.
Abstract
Combination antiretroviral therapy (cART) can suppress HIV infection but cannot completely eradicate the virus. A major obstacle in the quest for a cure is the difficulty in targeting and measuring latently infected cells. To date, a single person seems to have been cured of HIV. Hematopoietic stem cell transplantation (HSCT) preceded this cancer patient's long-term sustained HIV remission but researchers have been unable to replicate this cure and the mechanisms that led to HIV remission remain to be established. In February 2014, the National Institute of Allergy and Infectious Diseases sponsored a workshop that provided a venue for in-depth discussion of whether HSCT could be exploited to cure HIV in cancer patients requiring such procedures. Participants also discussed how HSCT might be applied to a broader community of HIV infected persons in whom the risks of HSCT currently outweigh the likelihood and benefits of HIV cure.
|
|
| |
| |
|
|
|
